Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Eli Lilly expects Alzheimer’s drugs to gain wider approval from Medicare

April 21, 2023 Reprints

Eli Lilly & Co. expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, Reuters reports. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi, a rival drug from partners Eisai Co. Ltd. and Biogen Inc., is also expected in the coming months.

Help

Eli Lilly expects Alzheimer’s drugs to gain wider approval from Medicare

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources